修饰未折叠蛋白反应诱导骨髓瘤细胞分化的实验研究
|
摘要
多发性骨髓瘤(multiple myeloma, MM)是一种浆细胞恶性肿瘤,以骨髓中异常浆细胞恶性增殖、分泌单克隆免疫球蛋白、正常免疫球蛋白受到抑制以及溶骨病变为特征。发生率占血液系统肿瘤的10%,占所有肿瘤的1%,死亡率占所有肿瘤的2%。美国癌症学会统计表明,2009年美国MM的新发病例约为20,580,包括男性患者11,680例,女性患者8900例,死亡约10,580例,MM发病率仅次于非霍奇金淋巴瘤,成为血液系统的第二位常见的恶性肿瘤。在我国也呈逐年升高的趋势。MM的治疗主要包括传统化疗,造血干细胞移植以及新药治疗。目前,新的靶向治疗药物已经成为治疗MM的重要手段,但就目前而言,骨髓瘤仍是不可治愈的疾病。维甲酸在诱导分化治疗急性早幼粒细胞白血病领域取得的巨大成功,鼓舞人们进行深入研究肿瘤的分化治疗策略。但在诱导骨髓瘤细胞分化方面其作用机制尚未完全阐明。因此,需要对其分子生物学机制进一步研究,以便为临床新药的开发与使用提供理论依据,进而制定新的联合用药方案,提高临床疗效。
内质网(endoplasmic reticulum, ER)是真核细胞中负责分泌性蛋白折叠和组装的细胞器。当细胞在病原感染、化学损伤、遗传突变、营养剥夺,以及正常分化(如B细胞分化)等各种内外源因素刺激下,ER中未折叠或错误折叠的蛋白增多,出现ER应激(ER stress),应激信号能通过ER膜传递到细胞核中,继而引起一系列特定的靶基因转录上调和蛋白质翻译水平下调,以使细胞能继续存活,这种反应就是未折叠蛋白反应(unfolded protein response, UPR)。MM细胞是浆细胞克隆增生性肿瘤,同正常浆细胞一样,骨髓瘤细胞具有高度发达和扩张的粗面ER,每秒钟能产生成千上万个免疫球蛋白分子,大量的免疫球蛋白在分泌之前必须经过ER的正确折叠和组装。如果这些蛋白不能被正确折叠,就会出现ER应激,诱导UPR的产生。浆细胞通过UPR减少免疫球蛋白分子的翻译,增加ER伴侣分子GRP78(glucose regulating protein 78)和GRP94(glucose regulating protein 94)以及折叠酶的表达,增强ER相关蛋白质降解途径(ER-associated degradation, ERAD)活性,提高细胞处理未折叠蛋白的能力,使之存活。
目前研究显示ER膜上有3种跨膜蛋白感应ER应激：PERK(PKR-like ER kinase)、ATF6(activating transcription factor-6)以及具有激酶和核酸内切酶活性的IRE1(inositol-requiring enzyme 1)。活化后的IRE1具有核酸内切酶活性,对XBP-1 mRNA进行剪接形成376aa的XBP-1剪接蛋白(XBP-1s);未经剪接的XBP-1 mRNA则形成261aa的蛋白(XBP-1u)。XBP-1是具有b-zip结构的转录因子,大量证据表明XBP-1对B细胞分化成熟为浆细胞,并分泌免疫球蛋白是至关重要的,为浆细胞分化所必需。XBP-1-/-的B淋巴细胞胞浆中可以表达免疫球蛋白,但不能大量的分泌免疫球蛋白,也不能完成B淋巴细胞的最终分化过程；在XBP-1-/-的B淋巴细胞中经基因转染后重新表达XBP-1 mRNA,可以有效地恢复免疫球蛋白的分泌。因此,XBP-1在UPR时表达上调,是UPR的关键靶基因,也对浆细胞的成熟、分化具有重要意义。
目前研究显示UPR在正常B细胞向浆细胞的分化过程中起重要的作用,没有UPR,浆细胞不能完成最终的分化和分泌免疫球蛋白。XBP-1在UPR活化时表达上调,并增加UPR靶基因伴侣分子GRP78和GRP94的表达,调节UPR。XBP-1也是UPR反应元件中与浆细胞分化相关的唯一转录因子。
当前研究国际上对诱导分化治疗MM研究甚少,尤其通过修饰未折叠蛋白反应诱导MM分化还是空白。因此,我们设想通过UPR的经典诱导剂二硫苏糖醇(DTT)或衣霉素(tunicamycin)诱导MM细胞发生UPR,观察对MM细胞分化的影响,研究XBP-1u、XBP-1s以及下游的伴侣分子GRP78、GRP94等的表达,然后采用RNAi等技术,影响XBP-1u、XBP-1s等的表达修饰UPR,最终达到明确诱导MM细胞分化的机制。本实验研究包括以下三个部分：
第一部分小剂量UPR诱导剂诱导骨髓瘤细胞分化的实验研究
目的探讨小剂量UPR诱导剂对骨髓瘤细胞的分化作用。
方法用小剂量UPR诱导剂(TM, DTT)处理MM细胞株U266, RPMI-8226。Annix V检测细胞的凋亡率。经细胞涂片,瑞氏染色后,显微镜下观察细胞形态；流式检测检测细胞表面CD49e的表达率；用人λ轻链ELISA试剂盒检测细胞培养上清液中轻链蛋白的浓度。
结果UPR诱导剂TM 0.4μmol/L, DTT 0.5mmol/L处理骨髓瘤细胞株U266,RPMI-8226 72小时后,Annix V检测细胞的凋亡率均低于5%。细胞形态学观察与对照组相比即可见到细胞胞核缩小,胞浆丰富,核浆比例下降,核仁减少或消失,核染色质变粗、变密。有些细胞具有典型的碱性胞浆,胞浆丰富,出现胞核偏心,核染色质粗糙,凝聚成块状,着色深,排列成车轮状,,呈现成熟浆细胞特有的形态改变,有别于细胞凋亡的早期形态学改变。
U266细胞CD49e的阳性率在对照组8.61±0.82%,TM处理72h后,U266细胞CD49e的阳性率为43.15±3.78%,有统计学差异(p<0.01),DTT处理72h后CD49e的阳性率为38.08±2.9%,有统计学差异(p<0.01)。RPMI-8226细胞CD49e的阳性率对照4.89±0.37%,TM处理72h后,CD49e的阳性率为25.54±2.67%,有统计学差异(p<0.05)；DTT处理72h后CD49e的阳性率为11.83±1.38%(p<0.05)。
U266细胞的培养上清液中轻链蛋白的浓度,对照组456.25±19.07ng/ml, TM处理72h组,692.35±45.4ng/ml,有统计学差异(p<0.01),DTT处理72h后,轻链蛋白的浓度为614.42±22.67ng/ml,有统计学差异(p<0.05)。
RPMI-8226细胞的培养上清液中轻链蛋白的浓度,对照组292.24±23.59ng/ml,TM处理72h组,407.16±18.09,有统计学差异(p<0.01),DTT处理72h后,轻链蛋白的浓度为478.35±15.37g／ml,有统计学差异(p<0.05)。
在原代细胞经UPR诱导剂处理72小时后,也得到有类似的结果,细胞具有形态学分化的表现,CD49e细胞的阳性率增加,培养上清液中轻链蛋白的浓度增加。
结论小剂量UPR诱导剂可以诱导骨髓瘤细胞株和原代细胞进一步的分化。
第二部分UPR诱导剂诱导骨髓瘤细胞分化过程中相关基因表达情况的研究
目的研究小剂量UPR诱导剂(TM, DTT)在诱导骨髓瘤细胞分化过程中,未折蛋白反应相关基因GRP78,GRP94的转录水平变化,与UPR和B细胞分化密切相关的XBP-1u, XBP-1s在转录和蛋白翻译水平的变化。
方法小剂量UPR诱导剂(TM, DTT)处理骨髓瘤细胞株U266,RPMI-8226,荧光Realtime PCR检测基因GRP78, GRP94, XBP-1u,, XBP-1s的转录水平变化,Western Blot检测XBP-1u, XBP-1s蛋白翻译水平的变化。
结果小剂量UPR诱导剂(TM, DTT)处理骨髓瘤细胞株U266,RPMI-8226后与对照组相比,荧光Realtime PCR检测基因GRP78, GRP94, XBP-1u,的转录水平是明显上调的,上调水平约1.5～3.12倍,而XBP-1s的转录水平是下降的。Western Blot检测XBP-1u的翻译水平是相对增加的,而XBP-1s的蛋白翻译水平下调。
结论在骨髓瘤细胞的诱导分化过程中发生了未折叠蛋白反应,XBP-1u的转录和翻译水平是相对增加的。
第三部分调控基因XBP-1u/XBP-1s表达对骨髓瘤细胞分化的影响
目的研究基因XBP-1u/XBP-1s表达水平的差异对骨髓瘤细胞分化的影响。
方法分别采用siRNA沉默XBP-1u的表达,构建过表达质粒转染骨髓瘤细胞过表达基因XBP-1u和XBP-1s后,通过形态学观察,流式检测细胞表面CD49e的表达率,和ELISA试剂盒检测培养上清中轻链蛋白的含量。
结果采用siRNA沉默XBP-1u的表达后,骨髓瘤细胞的进一步分化被阻断；过表达XBP-1u可以促进骨髓瘤细胞的分化,表现为形态学上分化成熟表现,CD49e的阳性率增加,细胞上清液中轻链含量是增加的；而过表达XBP-1s则不能促进骨髓瘤细胞的分化。
结论XBP-1的表达水平与骨髓瘤细胞的分化密切相关,其中XBP-1u的上调在其中起着重要作用。
Multiple myeloma (MM) is a neoplasm of malignant plasma cells, characterized by accumulation of malignant plasma cells in the bone marrow, production of a monoclonal protein, reduction in uninvolved immunoglobulin and lytic bone lesions. It accounted for 10% of hematological malignancies and 1% of all cancers. It represents approximately 2% of all cancer deaths.The American Cancer Society has estimated 20,580 new cancer cases of MM in the United States in 2009, including 11,680 cases in men and 8900 cases in women, with an estimated 10,580 deaths. MM is the second most prevalent blood cancer after non-Hodgkin's lymphoma. Its incidence also appears to be increasing in our country. The treatments of MM include conventional chemotherapy, hematopoietic stem cell transplantation and new drugs. And multiple myeloma is still incurable nowadays. As to all-trans retinoic acid (ATRA) in inducing differentiation therapy took great effect in acute promyelocytic leukemia. People try to test new strategies to cancer therapy. The mechanism in induction of myeloma cells'differentiation is unclear. Therefore, further study on their molecular biology mechanism is needed. Further understanding of the mechanism will be useful to a new agent development and its clinical application, make sense to design new combinations of therapies to raise clinical response.
Endoplasmic reticulum (ER) is an organelle of eukaryotic cells, and it is major in r secretary protein folding and assembly of the secreting protein. When the cells in pathogen infection, chemical injury, genetic mutations, nutritional deprivation, as well as normal differentiation (such as B cell differentiation), and other internal and external source of stimulation factors, unfolded or misfolded proteins accumulated in ER, and induce cell stress occurs (ER stress), stress signals pass through the ER membrane to the nucleus, and then cause a series of specific target gene transcription regulated and protein translation level down-regulated, so that cells can survive, and this reaction is called unfolded protein response (UPR). MM are the plasma cell clone proliferate tumors, the same as normal plasma cells, myeloma cells have highly developed and expansion of rough ER, can produce tens of thousands of immunoglobulin molecules per second, a large quantity of immunoglobulin must be the correct folding and assembly in the ER before secretion. If these proteins can't be correctly folded, there will be ER stress, and induced UPR. Plasma cells through UPR reducing the translation of immunoglobulin molecules, increasing ER Chaperone GRP78 (glucose regulating protein 78) and GRP94 (glucose regulating protein 94), as well as expression of folding enzymes in the ER associated protein degradation pathway increased (ER-associated degradation, ERAD) activity, to increase processing capacity of unfolded proteins to make cell survival.
The current study shows that there are three kinds of transmembrane protein of ER stress sensors in ER membrane:PERK (PKR-like ER kinase), ATF6 (activating transcription factor-6), as well as IRE1 (inositol-requiring enzyme 1).with the kinase and endonuclease activity. IRE1 with endonuclease activity after the activation, carried out on XBP-1 splicing. XBP-1 mRNA splicing form translation of 376aa protein (XBP-1s); and the unspliced XBP-1 mRNA will be translated to 261aa protein (XBP-1u). XBP-1 is a transcription factors with b-zip structure. Some studies revealed that XBP-1 is critical for plasma cell differentiation and maturation, and is necessary for secreting immunoglobulin. XBP-1(?) B-lymphocytes can express cytoplasm immunoglobulin, but can not secretary a large amount of immunoglobulin, it can not complete the final differentiation of B lymphocytes; in XBP-1(?) B-lymphocytes the gene re-expression of transfected XBP-1 mRNA in B lymphocytes, can effectively restore the secretion of immunoglobulin. Therefore, during the UPR, the XBP-1 expression increases, and XBP-1 is a key UPR target genes, is important to the plasma cells maturation and differentiation.
The current studies have shown that UPR played a key role in the process of normal B-cell differentiation to plasma cells. Without UPR, plasma cells can not complete the final differentiation and secretion of immunoglobulin. Expression of XBP-1 up-regulated during the UPR activation and increased UPR target genes chaperone GRP78, GRP94 expression, regulating UPR. XBP-1 is the only one transcription factor of UPR-responsive element which related to the plasma cell differentiation.
Currently, little International Research studied on the MM-induced differentiation therapies. Particularly it is still blank through the modification of unfolded protein response to induce the differentiation of MM. Therefore, we tested the adoption of the classic UPR inducer dithiothreitol (DTT) or tunicamycin (tunicamycin) to induce UPR and cell differentiation on MM cells. Observe the impact on MM cells' differentiation. To study the XBP-lu, XBP-1s, as well as the expression of downstream Chaperone GRP78/GRP94, and then using RNAi technologies interfere the XBP-1u, XBP-1s expression to modify UPR, and finally identify the mechanism of mycelia cells induced further differentiation. Experimental studies include the following three parts:
PartⅠ
Study on Low-Dose UPR Inducing Agents Induced Myeloma Cell Differentiation
Objective To investigate the effect of low-dose UPR inducers in myeloma cell differentiation.
Methods MM cell lines U266, RPMI-8226 were treated with a small dose of UPR inducer (TM, DTT). cell apoptosis detection by Annexin V. observed he cell morphology changes under the microscope after the cell smear, Wright stain; expression of CD49e on the cell surface was detect by flow cytometry; concentrations of light chain protein in cell culture supernatant were detected byλlight chain ELISA detection kit
Results Myeloma cell lines U266, RPMI-8226 were treated by UPR inducers TM 0.4μmol/L, DTT 0.5mmol/L after treatment 72 hours, apoptosis rate were evaluated by Annexin V positive rate was less than 5%. Compared with the control group, Cell morphology changed to mature feature, the cell nucleus narrowed, rich in cytoplasm, the ratio of nucleus and cytoplasm declined nucleolus disappearance, or reduction of nuclear staining. Some cells have a typical alkaline cytoplasm, rich in cytoplasm. With eccentric nuclei, coarse nuclear chromatin, massive form, arranged in the wheel-shaped, the morphological changes were quite different from the morphological changes of cell early apoptosis. The CD49e positive rate of U266 cells, in control group were 8.61±0.82%, after TM treatment 72h, CD49e positive rate was 43.15±3.78%, a statistically significant difference (p<0.01), after DTT treatment 72h CD49e positive rate was 38.08±2.9%, there is significant difference (p<0.01). RPMI-8226 cells, CD49e positive rate of the control group were 4.89±0.37%, after TM, treatment 72h, CD49e positive rate were 25.54±2.67%, a statistically significant difference (p<0.05); after DTT treatment 72h, CD49e positive rate were 11.83±1.38%(p<0.05). concentration of light chain protein of the cell culture supernatant in the U266 control group 456.25±19.07ng/ml, after TM treatment 72h were 692.35±45.4ng/ml, a statistically significant difference (p<0.01), after DTT treatment 72h concentration of light chain protein were 614.42±22.67ng/ml, a statistically significant difference (p<0.05).
RPMI-8226 cell lines in the control group were 292.24±23.59ng/ml, after TM treatment 72h were 407.16±18.09ng/ml, a statistic significant difference (p<0.01), after DTT treatment 72h Light chain protein concentration were 478.35±15.37ng/ml, a statistically significant difference (p<0.05).
In primary cells treated UPR inducers by the 72 hours later, also had similar results, the with the mature morphological feature, CD49e positive cells increased, concentration of light chain protein in the supernatant up-regulated.
Conclusion Low-dose UPR inducing agents tunicamycin and DTT can induce myeloma cell lines and primary cells further differentiation.
PartⅡ
Study on Related Gene Expression in UPR Inducing Agents Induced Myeloma Cell Differentiation
Objective To study the unfolded protein response related genes GRP78, GRP94 changes of transcription level in B cell differentiation with the low dose UPR inducers (TM, DTT) closely related to myeloma cell induction of and differentiation process, changes of XBP-1u, XBP-1s in the mRNA transcription and protein translation level.
Methods Human myeloma cell lines U266, RPMI-8226 were treated with low-dose UPR inducer (TM, DTT), gene GRP78, GRP94, XBP-1u,, XBP-1s transcription level changes were detected by fluorescence Realtime PCR, XBP-1u, XBP-1s protein translation level changes. By Western Blot Detection
Results after the treatment of low-dose UPR inducer (TM, DTT) compared with the control group the gene GRP78, GRP94, XBP-1u, transcription levels were significantly up-regulated, and increases the level were about 1.5 to 3.12 folds, while the transcription of XBP-1s levels down-regulated. XBP-1u had a relative up-regulated in the level of translation, while XBP-1s protein translation levels were down-regulated by Western Blot
Conclusion UPR was activated during the induction of myeloma cell differentiation, XBP-1u was relative up-regulated both in transcription and translation levels.
PartⅢ
Regulation of XBP-1u/XBP-1s Gene Expression on Myeloma Cells Differentiation
Objective To identify the different expression level of gene XBP-1u/XBP-1s on myeloma cell differentiation.
Methods siRNA interfere the expression of XBP-1u, and construction plasmid and transfected myeloma cells to over express gene XBP-1u and XBP-1s, through morphological observation, flow cytometry detection expression of CD49e in cell surface, and ELIS A kit test light chain protein in the cell culture supernatant.
Results after silencing the expression of XBP-1u, further differentiation of myeloma were blocked; over-expression of XBP-1u can promote the myeloma cells differentiation, showing the differentiation and maturation morphological changes, up-regulated the CD49e positive rate, and the concentration of light chain protein in the cell culture supernatant.
Conclusion XBP-1 is related to myeloma cell induction differentiation, in which up-regulation of XBP-1u played a key role in the differentiation.
内质网(endoplasmic reticulum, ER)是真核细胞中负责分泌性蛋白折叠和组装的细胞器。当细胞在病原感染、化学损伤、遗传突变、营养剥夺,以及正常分化(如B细胞分化)等各种内外源因素刺激下,ER中未折叠或错误折叠的蛋白增多,出现ER应激(ER stress),应激信号能通过ER膜传递到细胞核中,继而引起一系列特定的靶基因转录上调和蛋白质翻译水平下调,以使细胞能继续存活,这种反应就是未折叠蛋白反应(unfolded protein response, UPR)。MM细胞是浆细胞克隆增生性肿瘤,同正常浆细胞一样,骨髓瘤细胞具有高度发达和扩张的粗面ER,每秒钟能产生成千上万个免疫球蛋白分子,大量的免疫球蛋白在分泌之前必须经过ER的正确折叠和组装。如果这些蛋白不能被正确折叠,就会出现ER应激,诱导UPR的产生。浆细胞通过UPR减少免疫球蛋白分子的翻译,增加ER伴侣分子GRP78(glucose regulating protein 78)和GRP94(glucose regulating protein 94)以及折叠酶的表达,增强ER相关蛋白质降解途径(ER-associated degradation, ERAD)活性,提高细胞处理未折叠蛋白的能力,使之存活。
目前研究显示ER膜上有3种跨膜蛋白感应ER应激：PERK(PKR-like ER kinase)、ATF6(activating transcription factor-6)以及具有激酶和核酸内切酶活性的IRE1(inositol-requiring enzyme 1)。活化后的IRE1具有核酸内切酶活性,对XBP-1 mRNA进行剪接形成376aa的XBP-1剪接蛋白(XBP-1s);未经剪接的XBP-1 mRNA则形成261aa的蛋白(XBP-1u)。XBP-1是具有b-zip结构的转录因子,大量证据表明XBP-1对B细胞分化成熟为浆细胞,并分泌免疫球蛋白是至关重要的,为浆细胞分化所必需。XBP-1-/-的B淋巴细胞胞浆中可以表达免疫球蛋白,但不能大量的分泌免疫球蛋白,也不能完成B淋巴细胞的最终分化过程；在XBP-1-/-的B淋巴细胞中经基因转染后重新表达XBP-1 mRNA,可以有效地恢复免疫球蛋白的分泌。因此,XBP-1在UPR时表达上调,是UPR的关键靶基因,也对浆细胞的成熟、分化具有重要意义。
目前研究显示UPR在正常B细胞向浆细胞的分化过程中起重要的作用,没有UPR,浆细胞不能完成最终的分化和分泌免疫球蛋白。XBP-1在UPR活化时表达上调,并增加UPR靶基因伴侣分子GRP78和GRP94的表达,调节UPR。XBP-1也是UPR反应元件中与浆细胞分化相关的唯一转录因子。
当前研究国际上对诱导分化治疗MM研究甚少,尤其通过修饰未折叠蛋白反应诱导MM分化还是空白。因此,我们设想通过UPR的经典诱导剂二硫苏糖醇(DTT)或衣霉素(tunicamycin)诱导MM细胞发生UPR,观察对MM细胞分化的影响,研究XBP-1u、XBP-1s以及下游的伴侣分子GRP78、GRP94等的表达,然后采用RNAi等技术,影响XBP-1u、XBP-1s等的表达修饰UPR,最终达到明确诱导MM细胞分化的机制。本实验研究包括以下三个部分：
第一部分小剂量UPR诱导剂诱导骨髓瘤细胞分化的实验研究
目的探讨小剂量UPR诱导剂对骨髓瘤细胞的分化作用。
方法用小剂量UPR诱导剂(TM, DTT)处理MM细胞株U266, RPMI-8226。Annix V检测细胞的凋亡率。经细胞涂片,瑞氏染色后,显微镜下观察细胞形态；流式检测检测细胞表面CD49e的表达率；用人λ轻链ELISA试剂盒检测细胞培养上清液中轻链蛋白的浓度。
结果UPR诱导剂TM 0.4μmol/L, DTT 0.5mmol/L处理骨髓瘤细胞株U266,RPMI-8226 72小时后,Annix V检测细胞的凋亡率均低于5%。细胞形态学观察与对照组相比即可见到细胞胞核缩小,胞浆丰富,核浆比例下降,核仁减少或消失,核染色质变粗、变密。有些细胞具有典型的碱性胞浆,胞浆丰富,出现胞核偏心,核染色质粗糙,凝聚成块状,着色深,排列成车轮状,,呈现成熟浆细胞特有的形态改变,有别于细胞凋亡的早期形态学改变。
U266细胞CD49e的阳性率在对照组8.61±0.82%,TM处理72h后,U266细胞CD49e的阳性率为43.15±3.78%,有统计学差异(p<0.01),DTT处理72h后CD49e的阳性率为38.08±2.9%,有统计学差异(p<0.01)。RPMI-8226细胞CD49e的阳性率对照4.89±0.37%,TM处理72h后,CD49e的阳性率为25.54±2.67%,有统计学差异(p<0.05)；DTT处理72h后CD49e的阳性率为11.83±1.38%(p<0.05)。
U266细胞的培养上清液中轻链蛋白的浓度,对照组456.25±19.07ng/ml, TM处理72h组,692.35±45.4ng/ml,有统计学差异(p<0.01),DTT处理72h后,轻链蛋白的浓度为614.42±22.67ng/ml,有统计学差异(p<0.05)。
RPMI-8226细胞的培养上清液中轻链蛋白的浓度,对照组292.24±23.59ng/ml,TM处理72h组,407.16±18.09,有统计学差异(p<0.01),DTT处理72h后,轻链蛋白的浓度为478.35±15.37g／ml,有统计学差异(p<0.05)。
在原代细胞经UPR诱导剂处理72小时后,也得到有类似的结果,细胞具有形态学分化的表现,CD49e细胞的阳性率增加,培养上清液中轻链蛋白的浓度增加。
结论小剂量UPR诱导剂可以诱导骨髓瘤细胞株和原代细胞进一步的分化。
第二部分UPR诱导剂诱导骨髓瘤细胞分化过程中相关基因表达情况的研究
目的研究小剂量UPR诱导剂(TM, DTT)在诱导骨髓瘤细胞分化过程中,未折蛋白反应相关基因GRP78,GRP94的转录水平变化,与UPR和B细胞分化密切相关的XBP-1u, XBP-1s在转录和蛋白翻译水平的变化。
方法小剂量UPR诱导剂(TM, DTT)处理骨髓瘤细胞株U266,RPMI-8226,荧光Realtime PCR检测基因GRP78, GRP94, XBP-1u,, XBP-1s的转录水平变化,Western Blot检测XBP-1u, XBP-1s蛋白翻译水平的变化。
结果小剂量UPR诱导剂(TM, DTT)处理骨髓瘤细胞株U266,RPMI-8226后与对照组相比,荧光Realtime PCR检测基因GRP78, GRP94, XBP-1u,的转录水平是明显上调的,上调水平约1.5～3.12倍,而XBP-1s的转录水平是下降的。Western Blot检测XBP-1u的翻译水平是相对增加的,而XBP-1s的蛋白翻译水平下调。
结论在骨髓瘤细胞的诱导分化过程中发生了未折叠蛋白反应,XBP-1u的转录和翻译水平是相对增加的。
第三部分调控基因XBP-1u/XBP-1s表达对骨髓瘤细胞分化的影响
目的研究基因XBP-1u/XBP-1s表达水平的差异对骨髓瘤细胞分化的影响。
方法分别采用siRNA沉默XBP-1u的表达,构建过表达质粒转染骨髓瘤细胞过表达基因XBP-1u和XBP-1s后,通过形态学观察,流式检测细胞表面CD49e的表达率,和ELISA试剂盒检测培养上清中轻链蛋白的含量。
结果采用siRNA沉默XBP-1u的表达后,骨髓瘤细胞的进一步分化被阻断；过表达XBP-1u可以促进骨髓瘤细胞的分化,表现为形态学上分化成熟表现,CD49e的阳性率增加,细胞上清液中轻链含量是增加的；而过表达XBP-1s则不能促进骨髓瘤细胞的分化。
结论XBP-1的表达水平与骨髓瘤细胞的分化密切相关,其中XBP-1u的上调在其中起着重要作用。
Multiple myeloma (MM) is a neoplasm of malignant plasma cells, characterized by accumulation of malignant plasma cells in the bone marrow, production of a monoclonal protein, reduction in uninvolved immunoglobulin and lytic bone lesions. It accounted for 10% of hematological malignancies and 1% of all cancers. It represents approximately 2% of all cancer deaths.The American Cancer Society has estimated 20,580 new cancer cases of MM in the United States in 2009, including 11,680 cases in men and 8900 cases in women, with an estimated 10,580 deaths. MM is the second most prevalent blood cancer after non-Hodgkin's lymphoma. Its incidence also appears to be increasing in our country. The treatments of MM include conventional chemotherapy, hematopoietic stem cell transplantation and new drugs. And multiple myeloma is still incurable nowadays. As to all-trans retinoic acid (ATRA) in inducing differentiation therapy took great effect in acute promyelocytic leukemia. People try to test new strategies to cancer therapy. The mechanism in induction of myeloma cells'differentiation is unclear. Therefore, further study on their molecular biology mechanism is needed. Further understanding of the mechanism will be useful to a new agent development and its clinical application, make sense to design new combinations of therapies to raise clinical response.
Endoplasmic reticulum (ER) is an organelle of eukaryotic cells, and it is major in r secretary protein folding and assembly of the secreting protein. When the cells in pathogen infection, chemical injury, genetic mutations, nutritional deprivation, as well as normal differentiation (such as B cell differentiation), and other internal and external source of stimulation factors, unfolded or misfolded proteins accumulated in ER, and induce cell stress occurs (ER stress), stress signals pass through the ER membrane to the nucleus, and then cause a series of specific target gene transcription regulated and protein translation level down-regulated, so that cells can survive, and this reaction is called unfolded protein response (UPR). MM are the plasma cell clone proliferate tumors, the same as normal plasma cells, myeloma cells have highly developed and expansion of rough ER, can produce tens of thousands of immunoglobulin molecules per second, a large quantity of immunoglobulin must be the correct folding and assembly in the ER before secretion. If these proteins can't be correctly folded, there will be ER stress, and induced UPR. Plasma cells through UPR reducing the translation of immunoglobulin molecules, increasing ER Chaperone GRP78 (glucose regulating protein 78) and GRP94 (glucose regulating protein 94), as well as expression of folding enzymes in the ER associated protein degradation pathway increased (ER-associated degradation, ERAD) activity, to increase processing capacity of unfolded proteins to make cell survival.
The current study shows that there are three kinds of transmembrane protein of ER stress sensors in ER membrane:PERK (PKR-like ER kinase), ATF6 (activating transcription factor-6), as well as IRE1 (inositol-requiring enzyme 1).with the kinase and endonuclease activity. IRE1 with endonuclease activity after the activation, carried out on XBP-1 splicing. XBP-1 mRNA splicing form translation of 376aa protein (XBP-1s); and the unspliced XBP-1 mRNA will be translated to 261aa protein (XBP-1u). XBP-1 is a transcription factors with b-zip structure. Some studies revealed that XBP-1 is critical for plasma cell differentiation and maturation, and is necessary for secreting immunoglobulin. XBP-1(?) B-lymphocytes can express cytoplasm immunoglobulin, but can not secretary a large amount of immunoglobulin, it can not complete the final differentiation of B lymphocytes; in XBP-1(?) B-lymphocytes the gene re-expression of transfected XBP-1 mRNA in B lymphocytes, can effectively restore the secretion of immunoglobulin. Therefore, during the UPR, the XBP-1 expression increases, and XBP-1 is a key UPR target genes, is important to the plasma cells maturation and differentiation.
The current studies have shown that UPR played a key role in the process of normal B-cell differentiation to plasma cells. Without UPR, plasma cells can not complete the final differentiation and secretion of immunoglobulin. Expression of XBP-1 up-regulated during the UPR activation and increased UPR target genes chaperone GRP78, GRP94 expression, regulating UPR. XBP-1 is the only one transcription factor of UPR-responsive element which related to the plasma cell differentiation.
Currently, little International Research studied on the MM-induced differentiation therapies. Particularly it is still blank through the modification of unfolded protein response to induce the differentiation of MM. Therefore, we tested the adoption of the classic UPR inducer dithiothreitol (DTT) or tunicamycin (tunicamycin) to induce UPR and cell differentiation on MM cells. Observe the impact on MM cells' differentiation. To study the XBP-lu, XBP-1s, as well as the expression of downstream Chaperone GRP78/GRP94, and then using RNAi technologies interfere the XBP-1u, XBP-1s expression to modify UPR, and finally identify the mechanism of mycelia cells induced further differentiation. Experimental studies include the following three parts:
PartⅠ
Study on Low-Dose UPR Inducing Agents Induced Myeloma Cell Differentiation
Objective To investigate the effect of low-dose UPR inducers in myeloma cell differentiation.
Methods MM cell lines U266, RPMI-8226 were treated with a small dose of UPR inducer (TM, DTT). cell apoptosis detection by Annexin V. observed he cell morphology changes under the microscope after the cell smear, Wright stain; expression of CD49e on the cell surface was detect by flow cytometry; concentrations of light chain protein in cell culture supernatant were detected byλlight chain ELISA detection kit
Results Myeloma cell lines U266, RPMI-8226 were treated by UPR inducers TM 0.4μmol/L, DTT 0.5mmol/L after treatment 72 hours, apoptosis rate were evaluated by Annexin V positive rate was less than 5%. Compared with the control group, Cell morphology changed to mature feature, the cell nucleus narrowed, rich in cytoplasm, the ratio of nucleus and cytoplasm declined nucleolus disappearance, or reduction of nuclear staining. Some cells have a typical alkaline cytoplasm, rich in cytoplasm. With eccentric nuclei, coarse nuclear chromatin, massive form, arranged in the wheel-shaped, the morphological changes were quite different from the morphological changes of cell early apoptosis. The CD49e positive rate of U266 cells, in control group were 8.61±0.82%, after TM treatment 72h, CD49e positive rate was 43.15±3.78%, a statistically significant difference (p<0.01), after DTT treatment 72h CD49e positive rate was 38.08±2.9%, there is significant difference (p<0.01). RPMI-8226 cells, CD49e positive rate of the control group were 4.89±0.37%, after TM, treatment 72h, CD49e positive rate were 25.54±2.67%, a statistically significant difference (p<0.05); after DTT treatment 72h, CD49e positive rate were 11.83±1.38%(p<0.05). concentration of light chain protein of the cell culture supernatant in the U266 control group 456.25±19.07ng/ml, after TM treatment 72h were 692.35±45.4ng/ml, a statistically significant difference (p<0.01), after DTT treatment 72h concentration of light chain protein were 614.42±22.67ng/ml, a statistically significant difference (p<0.05).
RPMI-8226 cell lines in the control group were 292.24±23.59ng/ml, after TM treatment 72h were 407.16±18.09ng/ml, a statistic significant difference (p<0.01), after DTT treatment 72h Light chain protein concentration were 478.35±15.37ng/ml, a statistically significant difference (p<0.05).
In primary cells treated UPR inducers by the 72 hours later, also had similar results, the with the mature morphological feature, CD49e positive cells increased, concentration of light chain protein in the supernatant up-regulated.
Conclusion Low-dose UPR inducing agents tunicamycin and DTT can induce myeloma cell lines and primary cells further differentiation.
PartⅡ
Study on Related Gene Expression in UPR Inducing Agents Induced Myeloma Cell Differentiation
Objective To study the unfolded protein response related genes GRP78, GRP94 changes of transcription level in B cell differentiation with the low dose UPR inducers (TM, DTT) closely related to myeloma cell induction of and differentiation process, changes of XBP-1u, XBP-1s in the mRNA transcription and protein translation level.
Methods Human myeloma cell lines U266, RPMI-8226 were treated with low-dose UPR inducer (TM, DTT), gene GRP78, GRP94, XBP-1u,, XBP-1s transcription level changes were detected by fluorescence Realtime PCR, XBP-1u, XBP-1s protein translation level changes. By Western Blot Detection
Results after the treatment of low-dose UPR inducer (TM, DTT) compared with the control group the gene GRP78, GRP94, XBP-1u, transcription levels were significantly up-regulated, and increases the level were about 1.5 to 3.12 folds, while the transcription of XBP-1s levels down-regulated. XBP-1u had a relative up-regulated in the level of translation, while XBP-1s protein translation levels were down-regulated by Western Blot
Conclusion UPR was activated during the induction of myeloma cell differentiation, XBP-1u was relative up-regulated both in transcription and translation levels.
PartⅢ
Regulation of XBP-1u/XBP-1s Gene Expression on Myeloma Cells Differentiation
Objective To identify the different expression level of gene XBP-1u/XBP-1s on myeloma cell differentiation.
Methods siRNA interfere the expression of XBP-1u, and construction plasmid and transfected myeloma cells to over express gene XBP-1u and XBP-1s, through morphological observation, flow cytometry detection expression of CD49e in cell surface, and ELIS A kit test light chain protein in the cell culture supernatant.
Results after silencing the expression of XBP-1u, further differentiation of myeloma were blocked; over-expression of XBP-1u can promote the myeloma cells differentiation, showing the differentiation and maturation morphological changes, up-regulated the CD49e positive rate, and the concentration of light chain protein in the cell culture supernatant.
Conclusion XBP-1 is related to myeloma cell induction differentiation, in which up-regulation of XBP-1u played a key role in the differentiation.
引文
[1].侯健,傅卫军,主编.多发性骨髓瘤及其相关疾病.上海：上海科学技术出版社.2002：1-9.
[2]. Wek RC, Cavener DR. Translational control and the unfolded protein response. Antioxid Redox Signal.2007;9(12):2357-71.
[3]. Schroder M, Kaufman RJ. ER stress and the unfolded protein response. Mutat Res. 2005;569(1-2):29-63.
[4]. Kim R, Emi M, Tanabe K, Murakami S. Role of the unfolded protein response in cell death. Apoptosis.2006;11(1):5-13.
[5]. Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest. 2002;110(10):1389-98.
[6]. Kohno K. How transmembrane proteins sense endoplasmic reticulum stress. Antioxid Redox Signal.2007;9(12):2295-303.
[7]. Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, Panning B, Shokat KM, La(?)ail MM, Walter P. IRE1 signaling affects cell fate during the unfolded protein response. Science.2007;318(5852):944-9.
[8]. Lee AS. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods.2005;35(4):373-81.
[9]. Koumenis C, Naczki C, Koritzinsky M, Rastani S, Diehl A, Sonenberg N, Koromilas A, Wouters BG. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol Cell Biol. 2002;22(21):7405-16.
[10]. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 2001;107(7):881-91.
[11]. Liou HC, Boothby MR, Finn PW, Davidon R, Nabavi N, Zeleznik-Le NJ, Ting JP, Glimcher LH. A new member of the leucine zipper class of proteins that binds to the HLA DR alpha promoter. Science.1990;247(4950):1581-4.
[12]. Shen J, Prywes R. ER stress signaling by regulated proteolysis of ATF6. Methods. 2005;35(4):382-9.
[13]. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol.2007;8(7):519-29.
[14]. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med.2004;351(18):1860-73.
[15]. Harada H, Kawano MM, Huang N, Harada Y, Iwato K, Tanabe O, Tanaka H, Sakai A, Asaoku H, Kuramoto A. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81(10):2658-63.
[16]. Greipp PR, Raymond NM, Kyle RA, O'Fallon WM. Multiple myeloma:significance of plasmablastic subtype in morphological classification. Blood.1985;65(2):305-10.
[17].Kawano MM, Huang N, Harada H, Harada Y, Sakai A, Tanaka H, Iwato K, Kuramoto A. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood. 1993;82(2):564-70.
[18].Hou J, Xiong H, Gao W, Jiang H.2-Methoxyestradiol at low dose induces differentiation of myeloma cells. Leuk Res.2005;29(9):1059-67.
[19].Zhou X, Jiang H, Hou J. Coordination of upregulated XBP-1 and downregulated c-myc during myeloma cell differentiation induced by 2-methoxyestradiol. Leuk Res.2007;31(9):1259-65.
[20].Gass JN, Jiang HY, Wek RC, Brewer JW. The unfolded protein response of B-lymphocytes: PERK-independent development of antibody-secreting cells. Molecular immunology. 2008;45(4):1035-43.
[21].Jiang H, Gao W, Sze DM, Xiong H, Hou J. Transcription factors Xbp-1, Blimp-1, and BSAP are involved in the regulation of plasmacytic differentiation induced by 2-methoxyestradiol in myeloma cell lines. Int J Hematol.2007;86(5):429-37.
[22].Iwakoshi NN, Lee AH, Glimcher LH. The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response. Immunological reviews. 2003;194:29-38.
[23].Lee AH, Iwakoshi NN, Glimcher LH. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol.2003;23(21):7448-59.
[24].Sriburi R, Jackowski S, Mori K, Brewer JW. XBP1:a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. The Journal of cell biology. 2004;167(1):35-41.
[25].Iwakoshi NN, Lee A-H, Vallabhajosyula P. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nature immunology.2003;4(4):321-9.
[26].Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA.2003 Aug 19;100(17):9946-51.
[27].Pyrko P, Schonthal AH, Hofman FM, Chen TC, Lee AS. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res. 2007;67(20):9809-16.
[28].Todd DJ, McHeyzer-Williams LJ, Kowal C, Lee AH, Volpe BT, Diamond B, McHeyzer-Williams MG, Glimcher LH. XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development. J Exp Med.2009;206(10):2151-9.
[29].Carrasco DR, Sukhdeo K, Protopopova M, Sinha R, Enos M, Carrasco DE, Zheng M, Mani M, Henderson J, Pinkus GS, Munshi N, Horner J, Ivanova EV, Protopopov A, Anderson KC, Tonon G, DePinho RA. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell.2007;11(4):349-60.
[30].Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics,2009. CA Cancer J Clin. 2009;59(4):225-49.
[31].Brenner H, Gondos A, Pulte D. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica.2009;94(2):270-5.
[32].Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P, Crowley J. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival:an analysis of 10 549 patients from the International Myeloma Working Group. Blood.2008;111(8):4039-47.
[33].Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood.2008;112(12):4445-51.
[34].Roussou M, Kastritis E, Migkou M, Psimenou E, Grapsa I, Matsouka C, Barmparousi D, Terpos E, Dimopoulos MA. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma.2008;49(5):890-5.
[35].Wang ZY, Chen Z. Acute promyelocytic leukemia:from highly fatal to highly curable. Blood. 2008;111(5):2505-15.
[36].Kinjo K, Kizaki M, Muto A, Fukuchi Y, Umezawa A, Yamato K, Nishihara T, Hata J, Ito M, Ueyama Y, Ikeda Y. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia.2000;14(3):431-8.
[37].Oida Y, Izuta H, Oyagi A, Shimazawa M, Kudo T, Imaizumi K, Hara H. Induction of BiP, an ER-resident protein, prevents the neuronal death induced by transient forebrain ischemia in gerbil. Brain Res.2008;1208:217-24.
[38].Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res.2005;65(14):6364-70.
[39].Granerus M, Engstrom W. The effects of glycosylation inhibitors on the proliferation of a Wilms tumour cell line. Anticancer Res.2000;20(2A):689-92.
[40].Dricu A, Carlberg M, Wang M, Larsson O. Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells:role of down-regulation of the insulin-like growth factor 1 receptor in induction of apoptosis. Cancer Res.1997;57(3):543-8.
[41].Oda T, Kosuge Y, Arakawa M, Ishige K, Ito Y. Distinct mechanism of cell death is responsible for tunicamycin-induced ER stress in SK-N-SH and SH-SY5Y cells. Neurosci Res.2008;60(1):29-39.
[42].Yoshida T, Shiraishi T, Horinaka M, Wakada M, Sakai T. Glycosylation modulates TRAIL-Rl/death receptor 4 protein:different regulations of two pro-apoptotic receptors for TRAIL by tunicamycin. Oncol Rep.2007;18(5):1239-42.
[43]. Jiang CC, Chen LH, Gillespie S, Kiejda KA, Mhaidat N, Wang YF, Thorne R, Zhang XD, Hersey P. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res. 2007;67(12):5880-8.
[1]. Malhotra JD, Kaufman RJ. The endoplasmic reticulum and the unfolded protein response. Seminars in cell & developmental biology.2007; 18(6):716-31.
[2]. Yamamoto K, Yoshida H, Kokame K, Kaufman RJ, Mori K. Differential contributions of ATF6 and XBP1 to the activation of endoplasmic reticulum stress-responsive cis-acting elements ERSE, UPRE and ERSE-Ⅱ. Journal of biochemistry.2004;136(3):343-50.
[3]. Hirota M, Kitagaki M, Itagaki H, Aiba S. Quantitative measurement of spliced XBP1 mRNA as an indicator of endoplasmic reticulum stress. The Journal of toxicological sciences.2006;31(2):149-56.
[4]. Iwakoshi NN, Lee A-H, Glimcher LH. The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response. Immunological 2003;194:29-38.
[5]. Blais JD, Filipenko V, Bi M, Harding HP, Ron D, Koumenis C, Wouters BG, Bell JC. Activating transcription factor 4 is translationally regulated by hypoxic stress. Molecular and cellular biology. 2004;24(17):7469-82.
[6]. Harris MN, Ozpolat B, Abdi F, Gu S, Legler A, Mawuenyega KG, Tirado-Gomez M, Lopez-Berestein G, Chen X. Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia. Blood. 2004;104(5):1314-23.
[7]. Hong M, Li M, Mao C, Lee AS. Endoplasmic reticulum stress triggers an acute proteasome-dependent degradation of ATF6. Journal of cellular biochemistry.2004;92(4):723-32.
[8]. Rutkowski DT, Kaufman RJ. A trip to the ER:coping with stress. Trends in cell biology. 2004;14(1):20-8.
[9]. Lee K, Tirasophon W, Shen X, Michalak M, Prywes R, Okada T, Yoshida H, Mori K, Kaufman RJ. IRE 1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes & development.2002;16(4):452-66.
[10]. Gass JN, Gifford NM, Brewer JW. Activation of an unfolded protein response during differentiation of antibody-secreting B cells. J Biol Chem.2002;277(50):49047-54.
[11]. Gu F, Nguyen DT, Stuible M, Dube N, Tremblay ML, Chevet E. Protein-tyrosine phosphatase 1B potentiates IRE1 signaling during endoplasmic reticulum stress. J Biol Chem.2004;279(48):49689-93.
[12]. Szegezdi E, Fitzgerald U, Samali A. Caspase-12 and ER-stress-mediated apoptosis:the story so far. Annals of the New York Academy of Sciences.2003;1010:186-94.
[13].Tan Y, Dourdin N, Wu C, De Veyra T, Elce JS, Greer PA. Ubiquitous calpains promote caspase-12 and JNK activation during endoplasmic reticulum stress-induced apoptosis. J Biol Chem. 2006;281(23):16016-24.
[14]. Jimbo A, Fujita E, Kouroku Y, Ohnishi J, Inohara N, Kuida K, Sakamaki K, Yonehara S, Momoi T. ER stress induces caspase-8 activation, stimulating cytochrome c release and caspase-9 activation. Exp Cell Res.2003;283(2):156-66.
[15]. Novoa I, Zhang Y, Zeng H, Jungreis R, Harding HP, Ron D. Stress-induced gene expression requires programmed recovery from translational repression. The EMBO journal.2003;22(5):1180-7.
[16]. Okada T, Yoshida H, Akazawa R, Negishi M, Mori K. Distinct roles of activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded protein response. The Biochemical journal.
2002；366(Pt 2)：585-94.
[17].Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell.2000;6(5):1099-108.
[18].Yoshida H, Matsui T, Hosokawa N, Kaufman RJ, Nagata K, Mori K. A time-dependent phase shift in the mammalian unfolded protein response. Dev Cell.2003;4(2):265-71.
[19].Ma Y, Hendershot LM. Delineation of a negative feedback regulatory loop that controls protein translation during endoplasmic reticulum stress. J Biol Chem.2003;278(37):34864-73.
[20].van Huizen R, Martindale JL, Gorospe M, Holbrook NJ. P58IPK, a novel endoplasmic reticulum stress-inducible protein and potential negative regulator of eIF2alpha signaling. J Biol Chem. 2003;278(18):15558-64.
[21].Kaufman RJ. Orchestrating the unfolded protein response in health and disease. The Journal of clinical investigation.2002;110(10):1389-98.
[22].Oida Y, Gopalan B, Miyahara R, Branch CD, Chiao P, Chada S, Ramesh R. Inhibition of nuclear factor-kappaB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogen-activated protein kinase kinase kinase 1 activation. Mol Cancer Ther.2007;6(4):1440-9.
[23].Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, Pouyssegur J, Yaniv M, Mechta-Grigoriou F. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell. 2004;118(6):781-94.
[24].Campese VM, Shaohua Y, Huiquin Z. Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension.2005;46(3):533-9.
[25].de Oliveira-Marques V, Cyrne L, Marinho HS, Antunes F. A quantitative study of NF-kappaB activation by H2O2:relevance in inflammation and synergy with TNF-alpha. J Immunol. 2007;178(6):3893-902.
[26].Engelbrecht AM, Esterhuyse J, du Toit EF, Lochner A, van Rooyen J. p38-MAPK and PKB/Akt, possible role players in red palm oil-induced protection of the isolated perfused rat heart? J Nutr Biochem.2006;17(4):265-71.
[27].Lee HB, Yu MR, Song JS, Ha H. Reactive oxygen species amplify protein kinase C signaling in high glucose-induced fibronectin expression by human peritoneal mesothelial cells. Kidney Int. 2004;65(4):1170-9.
[28].Liang T, Xu S, Yu J, Shen K, Li D, Zheng S. Activation pattern of mitogen-activated protein kinases in early phase of different size liver isografts in rats. Liver Transpl.2005;11(12):1527-32.
[29].Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, Sadri N, Yun C, Popko B, Paules R, Stojdl DF, Bell JC, Hettmann T, Leiden JM, Ron D. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell.2003;11(3):619-33.
[30].Tu BP, Weissman JS. Oxidative protein folding in eukaryotes:mechanisms and consequences. J Cell Biol.2004;164(3):341-6.
[31].Haynes CM, Titus EA, Cooper AA. Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death. Mol Cell.2004;15(5):767-76.
[32].Ikesugi K, Yamamoto R, Mulhern ML, Shinohara T. Role of the unfolded protein response (UPR) in cataract formation. Exp Eye Res.2006;83(3):508-16.
[1]. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics,2009. CA Cancer J Clin. 2009;59(4):225-49.
[2]. Kyle RA. Multiple myeloma:review of 869 cases. Mayo Clin Proc.1975;50(1):29-40.
[3]. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol.2005;23(15):3412-20.
[4].陶中飞,傅卫军,陈玉宝,袁振刚,王东星,侯健.206例多发性骨髓瘤预后因素分析及分期评价.癌症.2006；25(4)：461-4.
[5]. Tiedemann RE, Mao X, Shi CX, Zhu YX, Palmer SE, Sebag M, Marler R, Chesi M, Fonseca R, Bergsagel PL, Schimmer AD, Stewart AK. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest.2008; 118(5):1750-64.
[6]. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD, Jr., Brennan C, Depinho RA. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell.2006;9(4):313-25.
[7]. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa AM, Sotto JJ, Wetterwald M, Dumontet C, Fuzibet JG, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau JL, Facon T, Mathiot C. Genetic abnormalities and survival in multiple myeloma:the experience of the Intergroupe Francophone du Myelome. Blood.2007;109(8):3489-95.
[8].Chng WJ, Santana-Davila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Jacobus S, Blood E, Oken MM, Henderson K, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Fonseca R. Prognostic factors for hyperdiploid-myeloma:effects of chromosome 13 deletions and IgH translocations. Leukemia.2006;20(5):807-13.
[9].Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood.2004;104(3):607-18.
[10].Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J, Jr. Cyclin D dysregulation:an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106(1):296-303.
[11].Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD, Jr. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020-8.
[12].Fonseca R. Strategies for risk-adapted therapy in myeloma. Hematology Am Soc Hematol Educ Program.2007:304-10.
[13].Shaughnessy JD, Jr., Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276-84.
[14].Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P, Attal M, Harousseau JL, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients:a study of the Intergroupe Francophone du Myelome. J Clin Oncol.2008;26(29):4798-805.
[2]. Wek RC, Cavener DR. Translational control and the unfolded protein response. Antioxid Redox Signal.2007;9(12):2357-71.
[3]. Schroder M, Kaufman RJ. ER stress and the unfolded protein response. Mutat Res. 2005;569(1-2):29-63.
[4]. Kim R, Emi M, Tanabe K, Murakami S. Role of the unfolded protein response in cell death. Apoptosis.2006;11(1):5-13.
[5]. Kaufman RJ. Orchestrating the unfolded protein response in health and disease. J Clin Invest. 2002;110(10):1389-98.
[6]. Kohno K. How transmembrane proteins sense endoplasmic reticulum stress. Antioxid Redox Signal.2007;9(12):2295-303.
[7]. Lin JH, Li H, Yasumura D, Cohen HR, Zhang C, Panning B, Shokat KM, La(?)ail MM, Walter P. IRE1 signaling affects cell fate during the unfolded protein response. Science.2007;318(5852):944-9.
[8]. Lee AS. The ER chaperone and signaling regulator GRP78/BiP as a monitor of endoplasmic reticulum stress. Methods.2005;35(4):373-81.
[9]. Koumenis C, Naczki C, Koritzinsky M, Rastani S, Diehl A, Sonenberg N, Koromilas A, Wouters BG. Regulation of protein synthesis by hypoxia via activation of the endoplasmic reticulum kinase PERK and phosphorylation of the translation initiation factor eIF2alpha. Mol Cell Biol. 2002;22(21):7405-16.
[10]. Yoshida H, Matsui T, Yamamoto A, Okada T, Mori K. XBP1 mRNA is induced by ATF6 and spliced by IRE1 in response to ER stress to produce a highly active transcription factor. Cell. 2001;107(7):881-91.
[11]. Liou HC, Boothby MR, Finn PW, Davidon R, Nabavi N, Zeleznik-Le NJ, Ting JP, Glimcher LH. A new member of the leucine zipper class of proteins that binds to the HLA DR alpha promoter. Science.1990;247(4950):1581-4.
[12]. Shen J, Prywes R. ER stress signaling by regulated proteolysis of ATF6. Methods. 2005;35(4):382-9.
[13]. Ron D, Walter P. Signal integration in the endoplasmic reticulum unfolded protein response. Nat Rev Mol Cell Biol.2007;8(7):519-29.
[14]. Kyle RA, Rajkumar SV. Multiple myeloma. N Engl J Med.2004;351(18):1860-73.
[15]. Harada H, Kawano MM, Huang N, Harada Y, Iwato K, Tanabe O, Tanaka H, Sakai A, Asaoku H, Kuramoto A. Phenotypic difference of normal plasma cells from mature myeloma cells. Blood. 1993;81(10):2658-63.
[16]. Greipp PR, Raymond NM, Kyle RA, O'Fallon WM. Multiple myeloma:significance of plasmablastic subtype in morphological classification. Blood.1985;65(2):305-10.
[17].Kawano MM, Huang N, Harada H, Harada Y, Sakai A, Tanaka H, Iwato K, Kuramoto A. Identification of immature and mature myeloma cells in the bone marrow of human myelomas. Blood. 1993;82(2):564-70.
[18].Hou J, Xiong H, Gao W, Jiang H.2-Methoxyestradiol at low dose induces differentiation of myeloma cells. Leuk Res.2005;29(9):1059-67.
[19].Zhou X, Jiang H, Hou J. Coordination of upregulated XBP-1 and downregulated c-myc during myeloma cell differentiation induced by 2-methoxyestradiol. Leuk Res.2007;31(9):1259-65.
[20].Gass JN, Jiang HY, Wek RC, Brewer JW. The unfolded protein response of B-lymphocytes: PERK-independent development of antibody-secreting cells. Molecular immunology. 2008;45(4):1035-43.
[21].Jiang H, Gao W, Sze DM, Xiong H, Hou J. Transcription factors Xbp-1, Blimp-1, and BSAP are involved in the regulation of plasmacytic differentiation induced by 2-methoxyestradiol in myeloma cell lines. Int J Hematol.2007;86(5):429-37.
[22].Iwakoshi NN, Lee AH, Glimcher LH. The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response. Immunological reviews. 2003;194:29-38.
[23].Lee AH, Iwakoshi NN, Glimcher LH. XBP-1 regulates a subset of endoplasmic reticulum resident chaperone genes in the unfolded protein response. Mol Cell Biol.2003;23(21):7448-59.
[24].Sriburi R, Jackowski S, Mori K, Brewer JW. XBP1:a link between the unfolded protein response, lipid biosynthesis, and biogenesis of the endoplasmic reticulum. The Journal of cell biology. 2004;167(1):35-41.
[25].Iwakoshi NN, Lee A-H, Vallabhajosyula P. Plasma cell differentiation and the unfolded protein response intersect at the transcription factor XBP-1. Nature immunology.2003;4(4):321-9.
[26].Lee AH, Iwakoshi NN, Anderson KC, Glimcher LH. Proteasome inhibitors disrupt the unfolded protein response in myeloma cells. Proc Natl Acad Sci USA.2003 Aug 19;100(17):9946-51.
[27].Pyrko P, Schonthal AH, Hofman FM, Chen TC, Lee AS. The unfolded protein response regulator GRP78/BiP as a novel target for increasing chemosensitivity in malignant gliomas. Cancer Res. 2007;67(20):9809-16.
[28].Todd DJ, McHeyzer-Williams LJ, Kowal C, Lee AH, Volpe BT, Diamond B, McHeyzer-Williams MG, Glimcher LH. XBP1 governs late events in plasma cell differentiation and is not required for antigen-specific memory B cell development. J Exp Med.2009;206(10):2151-9.
[29].Carrasco DR, Sukhdeo K, Protopopova M, Sinha R, Enos M, Carrasco DE, Zheng M, Mani M, Henderson J, Pinkus GS, Munshi N, Horner J, Ivanova EV, Protopopov A, Anderson KC, Tonon G, DePinho RA. The differentiation and stress response factor XBP-1 drives multiple myeloma pathogenesis. Cancer Cell.2007;11(4):349-60.
[30].Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics,2009. CA Cancer J Clin. 2009;59(4):225-49.
[31].Brenner H, Gondos A, Pulte D. Expected long-term survival of patients diagnosed with multiple myeloma in 2006-2010. Haematologica.2009;94(2):270-5.
[32].Ludwig H, Durie BG, Bolejack V, Turesson I, Kyle RA, Blade J, Fonseca R, Dimopoulos M, Shimizu K, San Miguel J, Westin J, Harousseau JL, Beksac M, Boccadoro M, Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR, Joshua D, Attal M, Sonneveld P, Crowley J. Myeloma in patients younger than age 50 years presents with more favorable features and shows better survival:an analysis of 10 549 patients from the International Myeloma Working Group. Blood.2008;111(8):4039-47.
[33].Wang M, Dimopoulos MA, Chen C, Cibeira MT, Attal M, Spencer A, Rajkumar SV, Yu Z, Olesnyckyj M, Zeldis JB, Knight RD, Weber DM. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure. Blood.2008;112(12):4445-51.
[34].Roussou M, Kastritis E, Migkou M, Psimenou E, Grapsa I, Matsouka C, Barmparousi D, Terpos E, Dimopoulos MA. Treatment of patients with multiple myeloma complicated by renal failure with bortezomib-based regimens. Leuk Lymphoma.2008;49(5):890-5.
[35].Wang ZY, Chen Z. Acute promyelocytic leukemia:from highly fatal to highly curable. Blood. 2008;111(5):2505-15.
[36].Kinjo K, Kizaki M, Muto A, Fukuchi Y, Umezawa A, Yamato K, Nishihara T, Hata J, Ito M, Ueyama Y, Ikeda Y. Arsenic trioxide (As2O3)-induced apoptosis and differentiation in retinoic acid-resistant acute promyelocytic leukemia model in hGM-CSF-producing transgenic SCID mice. Leukemia.2000;14(3):431-8.
[37].Oida Y, Izuta H, Oyagi A, Shimazawa M, Kudo T, Imaizumi K, Hara H. Induction of BiP, an ER-resident protein, prevents the neuronal death induced by transient forebrain ischemia in gerbil. Brain Res.2008;1208:217-24.
[38].Shiraishi T, Yoshida T, Nakata S, Horinaka M, Wakada M, Mizutani Y, Miki T, Sakai T. Tunicamycin enhances tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis in human prostate cancer cells. Cancer Res.2005;65(14):6364-70.
[39].Granerus M, Engstrom W. The effects of glycosylation inhibitors on the proliferation of a Wilms tumour cell line. Anticancer Res.2000;20(2A):689-92.
[40].Dricu A, Carlberg M, Wang M, Larsson O. Inhibition of N-linked glycosylation using tunicamycin causes cell death in malignant cells:role of down-regulation of the insulin-like growth factor 1 receptor in induction of apoptosis. Cancer Res.1997;57(3):543-8.
[41].Oda T, Kosuge Y, Arakawa M, Ishige K, Ito Y. Distinct mechanism of cell death is responsible for tunicamycin-induced ER stress in SK-N-SH and SH-SY5Y cells. Neurosci Res.2008;60(1):29-39.
[42].Yoshida T, Shiraishi T, Horinaka M, Wakada M, Sakai T. Glycosylation modulates TRAIL-Rl/death receptor 4 protein:different regulations of two pro-apoptotic receptors for TRAIL by tunicamycin. Oncol Rep.2007;18(5):1239-42.
[43]. Jiang CC, Chen LH, Gillespie S, Kiejda KA, Mhaidat N, Wang YF, Thorne R, Zhang XD, Hersey P. Tunicamycin sensitizes human melanoma cells to tumor necrosis factor-related apoptosis-inducing ligand-induced apoptosis by up-regulation of TRAIL-R2 via the unfolded protein response. Cancer Res. 2007;67(12):5880-8.
[1]. Malhotra JD, Kaufman RJ. The endoplasmic reticulum and the unfolded protein response. Seminars in cell & developmental biology.2007; 18(6):716-31.
[2]. Yamamoto K, Yoshida H, Kokame K, Kaufman RJ, Mori K. Differential contributions of ATF6 and XBP1 to the activation of endoplasmic reticulum stress-responsive cis-acting elements ERSE, UPRE and ERSE-Ⅱ. Journal of biochemistry.2004;136(3):343-50.
[3]. Hirota M, Kitagaki M, Itagaki H, Aiba S. Quantitative measurement of spliced XBP1 mRNA as an indicator of endoplasmic reticulum stress. The Journal of toxicological sciences.2006;31(2):149-56.
[4]. Iwakoshi NN, Lee A-H, Glimcher LH. The X-box binding protein-1 transcription factor is required for plasma cell differentiation and the unfolded protein response. Immunological 2003;194:29-38.
[5]. Blais JD, Filipenko V, Bi M, Harding HP, Ron D, Koumenis C, Wouters BG, Bell JC. Activating transcription factor 4 is translationally regulated by hypoxic stress. Molecular and cellular biology. 2004;24(17):7469-82.
[6]. Harris MN, Ozpolat B, Abdi F, Gu S, Legler A, Mawuenyega KG, Tirado-Gomez M, Lopez-Berestein G, Chen X. Comparative proteomic analysis of all-trans-retinoic acid treatment reveals systematic posttranscriptional control mechanisms in acute promyelocytic leukemia. Blood. 2004;104(5):1314-23.
[7]. Hong M, Li M, Mao C, Lee AS. Endoplasmic reticulum stress triggers an acute proteasome-dependent degradation of ATF6. Journal of cellular biochemistry.2004;92(4):723-32.
[8]. Rutkowski DT, Kaufman RJ. A trip to the ER:coping with stress. Trends in cell biology. 2004;14(1):20-8.
[9]. Lee K, Tirasophon W, Shen X, Michalak M, Prywes R, Okada T, Yoshida H, Mori K, Kaufman RJ. IRE 1-mediated unconventional mRNA splicing and S2P-mediated ATF6 cleavage merge to regulate XBP1 in signaling the unfolded protein response. Genes & development.2002;16(4):452-66.
[10]. Gass JN, Gifford NM, Brewer JW. Activation of an unfolded protein response during differentiation of antibody-secreting B cells. J Biol Chem.2002;277(50):49047-54.
[11]. Gu F, Nguyen DT, Stuible M, Dube N, Tremblay ML, Chevet E. Protein-tyrosine phosphatase 1B potentiates IRE1 signaling during endoplasmic reticulum stress. J Biol Chem.2004;279(48):49689-93.
[12]. Szegezdi E, Fitzgerald U, Samali A. Caspase-12 and ER-stress-mediated apoptosis:the story so far. Annals of the New York Academy of Sciences.2003;1010:186-94.
[13].Tan Y, Dourdin N, Wu C, De Veyra T, Elce JS, Greer PA. Ubiquitous calpains promote caspase-12 and JNK activation during endoplasmic reticulum stress-induced apoptosis. J Biol Chem. 2006;281(23):16016-24.
[14]. Jimbo A, Fujita E, Kouroku Y, Ohnishi J, Inohara N, Kuida K, Sakamaki K, Yonehara S, Momoi T. ER stress induces caspase-8 activation, stimulating cytochrome c release and caspase-9 activation. Exp Cell Res.2003;283(2):156-66.
[15]. Novoa I, Zhang Y, Zeng H, Jungreis R, Harding HP, Ron D. Stress-induced gene expression requires programmed recovery from translational repression. The EMBO journal.2003;22(5):1180-7.
[16]. Okada T, Yoshida H, Akazawa R, Negishi M, Mori K. Distinct roles of activating transcription factor 6 (ATF6) and double-stranded RNA-activated protein kinase-like endoplasmic reticulum kinase (PERK) in transcription during the mammalian unfolded protein response. The Biochemical journal.
2002；366(Pt 2)：585-94.
[17].Harding HP, Novoa I, Zhang Y, Zeng H, Wek R, Schapira M, Ron D. Regulated translation initiation controls stress-induced gene expression in mammalian cells. Mol Cell.2000;6(5):1099-108.
[18].Yoshida H, Matsui T, Hosokawa N, Kaufman RJ, Nagata K, Mori K. A time-dependent phase shift in the mammalian unfolded protein response. Dev Cell.2003;4(2):265-71.
[19].Ma Y, Hendershot LM. Delineation of a negative feedback regulatory loop that controls protein translation during endoplasmic reticulum stress. J Biol Chem.2003;278(37):34864-73.
[20].van Huizen R, Martindale JL, Gorospe M, Holbrook NJ. P58IPK, a novel endoplasmic reticulum stress-inducible protein and potential negative regulator of eIF2alpha signaling. J Biol Chem. 2003;278(18):15558-64.
[21].Kaufman RJ. Orchestrating the unfolded protein response in health and disease. The Journal of clinical investigation.2002;110(10):1389-98.
[22].Oida Y, Gopalan B, Miyahara R, Branch CD, Chiao P, Chada S, Ramesh R. Inhibition of nuclear factor-kappaB augments antitumor activity of adenovirus-mediated melanoma differentiation-associated gene-7 against lung cancer cells via mitogen-activated protein kinase kinase kinase 1 activation. Mol Cancer Ther.2007;6(4):1440-9.
[23].Gerald D, Berra E, Frapart YM, Chan DA, Giaccia AJ, Mansuy D, Pouyssegur J, Yaniv M, Mechta-Grigoriou F. JunD reduces tumor angiogenesis by protecting cells from oxidative stress. Cell. 2004;118(6):781-94.
[24].Campese VM, Shaohua Y, Huiquin Z. Oxidative stress mediates angiotensin II-dependent stimulation of sympathetic nerve activity. Hypertension.2005;46(3):533-9.
[25].de Oliveira-Marques V, Cyrne L, Marinho HS, Antunes F. A quantitative study of NF-kappaB activation by H2O2:relevance in inflammation and synergy with TNF-alpha. J Immunol. 2007;178(6):3893-902.
[26].Engelbrecht AM, Esterhuyse J, du Toit EF, Lochner A, van Rooyen J. p38-MAPK and PKB/Akt, possible role players in red palm oil-induced protection of the isolated perfused rat heart? J Nutr Biochem.2006;17(4):265-71.
[27].Lee HB, Yu MR, Song JS, Ha H. Reactive oxygen species amplify protein kinase C signaling in high glucose-induced fibronectin expression by human peritoneal mesothelial cells. Kidney Int. 2004;65(4):1170-9.
[28].Liang T, Xu S, Yu J, Shen K, Li D, Zheng S. Activation pattern of mitogen-activated protein kinases in early phase of different size liver isografts in rats. Liver Transpl.2005;11(12):1527-32.
[29].Harding HP, Zhang Y, Zeng H, Novoa I, Lu PD, Calfon M, Sadri N, Yun C, Popko B, Paules R, Stojdl DF, Bell JC, Hettmann T, Leiden JM, Ron D. An integrated stress response regulates amino acid metabolism and resistance to oxidative stress. Mol Cell.2003;11(3):619-33.
[30].Tu BP, Weissman JS. Oxidative protein folding in eukaryotes:mechanisms and consequences. J Cell Biol.2004;164(3):341-6.
[31].Haynes CM, Titus EA, Cooper AA. Degradation of misfolded proteins prevents ER-derived oxidative stress and cell death. Mol Cell.2004;15(5):767-76.
[32].Ikesugi K, Yamamoto R, Mulhern ML, Shinohara T. Role of the unfolded protein response (UPR) in cataract formation. Exp Eye Res.2006;83(3):508-16.
[1]. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ. Cancer statistics,2009. CA Cancer J Clin. 2009;59(4):225-49.
[2]. Kyle RA. Multiple myeloma:review of 869 cases. Mayo Clin Proc.1975;50(1):29-40.
[3]. Greipp PR, San Miguel J, Durie BG, Crowley JJ, Barlogie B, Blade J, Boccadoro M, Child JA, Avet-Loiseau H, Kyle RA, Lahuerta JJ, Ludwig H, Morgan G, Powles R, Shimizu K, Shustik C, Sonneveld P, Tosi P, Turesson I, Westin J. International staging system for multiple myeloma. J Clin Oncol.2005;23(15):3412-20.
[4].陶中飞,傅卫军,陈玉宝,袁振刚,王东星,侯健.206例多发性骨髓瘤预后因素分析及分期评价.癌症.2006；25(4)：461-4.
[5]. Tiedemann RE, Mao X, Shi CX, Zhu YX, Palmer SE, Sebag M, Marler R, Chesi M, Fonseca R, Bergsagel PL, Schimmer AD, Stewart AK. Identification of kinetin riboside as a repressor of CCND1 and CCND2 with preclinical antimyeloma activity. J Clin Invest.2008; 118(5):1750-64.
[6]. Carrasco DR, Tonon G, Huang Y, Zhang Y, Sinha R, Feng B, Stewart JP, Zhan F, Khatry D, Protopopova M, Protopopov A, Sukhdeo K, Hanamura I, Stephens O, Barlogie B, Anderson KC, Chin L, Shaughnessy JD, Jr., Brennan C, Depinho RA. High-resolution genomic profiles define distinct clinico-pathogenetic subgroups of multiple myeloma patients. Cancer Cell.2006;9(4):313-25.
[7]. Avet-Loiseau H, Attal M, Moreau P, Charbonnel C, Garban F, Hulin C, Leyvraz S, Michallet M, Yakoub-Agha I, Garderet L, Marit G, Michaux L, Voillat L, Renaud M, Grosbois B, Guillerm G, Benboubker L, Monconduit M, Thieblemont C, Casassus P, Caillot D, Stoppa AM, Sotto JJ, Wetterwald M, Dumontet C, Fuzibet JG, Azais I, Dorvaux V, Zandecki M, Bataille R, Minvielle S, Harousseau JL, Facon T, Mathiot C. Genetic abnormalities and survival in multiple myeloma:the experience of the Intergroupe Francophone du Myelome. Blood.2007;109(8):3489-95.
[8].Chng WJ, Santana-Davila R, Van Wier SA, Ahmann GJ, Jalal SM, Bergsagel PL, Chesi M, Trendle MC, Jacobus S, Blood E, Oken MM, Henderson K, Kyle RA, Gertz MA, Lacy MQ, Dispenzieri A, Greipp PR, Fonseca R. Prognostic factors for hyperdiploid-myeloma:effects of chromosome 13 deletions and IgH translocations. Leukemia.2006;20(5):807-13.
[9].Hideshima T, Bergsagel PL, Kuehl WM, Anderson KC. Advances in biology of multiple myeloma: clinical applications. Blood.2004;104(3):607-18.
[10].Bergsagel PL, Kuehl WM, Zhan F, Sawyer J, Barlogie B, Shaughnessy J, Jr. Cyclin D dysregulation:an early and unifying pathogenic event in multiple myeloma. Blood. 2005;106(1):296-303.
[11].Zhan F, Huang Y, Colla S, Stewart JP, Hanamura I, Gupta S, Epstein J, Yaccoby S, Sawyer J, Burington B, Anaissie E, Hollmig K, Pineda-Roman M, Tricot G, van Rhee F, Walker R, Zangari M, Crowley J, Barlogie B, Shaughnessy JD, Jr. The molecular classification of multiple myeloma. Blood. 2006;108(6):2020-8.
[12].Fonseca R. Strategies for risk-adapted therapy in myeloma. Hematology Am Soc Hematol Educ Program.2007:304-10.
[13].Shaughnessy JD, Jr., Zhan F, Burington BE, Huang Y, Colla S, Hanamura I, Stewart JP, Kordsmeier B, Randolph C, Williams DR, Xiao Y, Xu H, Epstein J, Anaissie E, Krishna SG, Cottler-Fox M, Hollmig K, Mohiuddin A, Pineda-Roman M, Tricot G, van Rhee F, Sawyer J, Alsayed Y, Walker R, Zangari M, Crowley J, Barlogie B. A validated gene expression model of high-risk multiple myeloma is defined by deregulated expression of genes mapping to chromosome 1. Blood. 2007;109(6):2276-84.
[14].Decaux O, Lode L, Magrangeas F, Charbonnel C, Gouraud W, Jezequel P, Attal M, Harousseau JL, Moreau P, Bataille R, Campion L, Avet-Loiseau H, Minvielle S. Prediction of survival in multiple myeloma based on gene expression profiles reveals cell cycle and chromosomal instability signatures in high-risk patients and hyperdiploid signatures in low-risk patients:a study of the Intergroupe Francophone du Myelome. J Clin Oncol.2008;26(29):4798-805.
© 2004-2018 中国地质图书馆版权所有 京ICP备05064691号 京公网安备11010802017129号 地址：北京市海淀区学院路29号 邮编：100083 电话：办公室：(+86 10)66554848；文献借阅、咨询服务、科技查新：66554700 |